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Abstract
The activation of heme oxygenase-1 (HO-1) appears 
to be an endogenous defensive mechanism used by 
cells to reduce inflammation and tissue damage in a 
number of injury models. HO-1, a stress-responsive 
enzyme that catabolizes heme into carbon monoxide 
(CO), biliverdin and iron, has previously been shown to 
protect grafts from ischemia/reperfusion and rejection. 
In addition, the products of the HO-catalyzed reac-
tion, particularly CO and biliverdin/bilirubin, have been 
shown to exert protective effects in the liver against 
a number of stimuli, as in chronic hepatitis C and in 
transplanted liver grafts. Furthermore, the induction of 
HO-1 expression can protect the liver against damage 
caused by a number of chemical compounds. More 
specifically, the CO derived from HO-1-mediated heme 
catabolism has been shown to be involved in the regu-
lation of inflammation; furthermore, administration of 
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low concentrations of exogenous CO has a protective 
effect against inflammation. Both murine and human 
HO-1 deficiencies have systemic manifestations associ-
ated with iron metabolism, such as hepatic overload 
(with signs of a chronic hepatitis) and iron deficiency 
anemia (with paradoxical increased levels of ferritin). 
Hypoxia induces HO-1 expression in multiple rodent, 
bovine and monkey cell lines, but interestingly, hypoxia 
represses expression of the human HO-1  gene in a 
variety of human cell types (endothelial cells, epithelial 
cells, T cells). These data suggest that HO-1 and CO 
are promising novel therapeutic molecules for patients 
with inflammatory diseases. In this review, we present 
what is currently known regarding the role of HO-1 in 
liver injuries and in particular, we focus on the implica-
tions of targeted induction of HO-1 as a potential ther-
apeutic strategy to protect the liver against chemically 
induced injury. 
© 2013 Baishideng. All rights reserved.
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HEME OXYGENASES
Heme oxygenases (HOs) are ubiquitous and essential en-
zymes for all eukaryotic organisms that depend on aero-
bic oxidation and electron transport via heme-containing 
proteins[1,2]. HOs were first recognized as catalyzing the 
rate-limiting step in the principal degradative mechanism 
of  heme (iron protoporphyrin IX)[2,3] catabolism. In a re-
action that requires oxygen and nicotinamide adenine di-
nucleotide phosphate (NADP), the heme ring is cleaved 
by HO to yield biliverdin, along with the concomitant re-
lease of  iron and the emission of  carbon monoxide (CO) 
(in equimolar quantities). Biliverdin (BV) is then reduced 
to bilirubin (BR) by biliverdin reductase[4] (Figure 1).
Two distinct isoforms of  HO (the products of  dif-
ferent genes) have been identified. HO-1 is a single 
transmembrane inducible protein found in endoplasmic 
reticulum, caveola, nuclei and mitochondria. It is ubiqui-
tously present in mammalian tissues such as liver, spleen, 
pancreas, intestine, kidney, heart, retina, prostate, lung, 
skin, brain, spinal cord, vascular smooth muscle cells and 
endothelial cells. Its expression is relatively low under 
physiological conditions, except in the spleen where the 
action of  HO-1 is critical to the recycling of  iron from 
senescent erythrocytes[5]. HO-2 shares 40% amino acid 
homology with HO-1; it is constitutively expressed and 
may provide an additional temporary buffering function 
against pro-oxidant heme by means of  sequestration (via 
additional heme binding sites located on the enzyme). It 
is localized to the mitochondria where it likely regulates 
a variety of  cellular functions. The existence of  a third 
distinct isoform of  HO encoded (HO-3) has been postu-
lated but it is now clear that this is a non-coding pseudo-
gene[1]. Both isoforms, HO-1 and HO-2, of  this enzyme 
catalyze the same enzymatic reaction, resulting in the 
degradation of  heme[6].
The role that HO-1 plays in the modulation of  the 
immune response has been increasingly studied within 
the field of  immunology and it is now recognized that 
HO-1 may act as a molecular brake on the activation, 
recruitment and amplification of  immune responses[7]. 
Over-expression of  HO-1 results in reduced expression 
of  endothelial-leukocyte adhesion molecules and reduced 
activity of  the nuclear factor-kB (NF-kB) pathway; con-
versely, HO-1-deficient animals exhibit increased levels 
of  monocyte chemo-attractant protein-1. In humans, 
HO-1 deficiency is associated with susceptibility to oxi-
dative stress and an increased pro-inflammatory state 
correlated with severe endothelial damage[8]. Mice lacking 
HO-1 develop progressive inflammatory diseases[9] and 
show enhanced sensitivity to lipopolysaccharide (LPS)-
induced toxemia. HO-1 deficiency shows partial embry-
onic lethality. HO-1 knockout mice display a progressive 
chronic inflammatory disease characterized by enlarged 
spleens and hepatic inflammatory lesions. Additionally, 
the protective properties of  HO-1 have been studied in a 
variety of  inflammatory models[6].
EXPRESSION AND TRANSCRIPTIONAL 
REGULATION OF HO-1
The human HO-1 gene is located on chromosome 22q12; 
it is approximately 14 kb long and contains 5 exons[8]. 
Control of  HO-1 transcription is complex and tightly 
regulated, with differences in expression found between 
tissues, as well as between species[9]. A wide variety of  
stimuli have been shown to induce HO-1 expression, in-
cluding heme, heavy metals, hydrogen peroxide, oxidized 
low density lipoproteins, hyperoxia, hypoxia, endotoxins, 
nitric oxide (and nitric oxide donors), cytokines, angio-
tensin Ⅱ, shear stress and ultraviolet radiation[3] (Figure 
2). Its biological function is to provide a specific regula-
tory mechanism for control of  the level of  many heme 
proteins. Multiple regulatory elements control human 
HO-1 gene transcription. These elements contain numer-
ous transcription factor consensus binding sites in both 
the proximal and distal 5’ promoter sequences, as well 
as in an internal enhancer region. HO-1 gene expression 
can be up-regulated through its multiple stress response 
and cadmium response elements, as well as by numerous 
important transcription factors, including Jun B, activator 
proteins 1 and 2, and NF-kB[10]. Conversely, the transcrip-
tion factors Bach1 and Jun D act as negative regulators 
of  human HO-1 gene expression[2,11]. 
Hypoxia induces HO-1 expression in multiple rodent, 
bovine and monkey cell lines, but interestingly, hypoxia 
represses expression of  the human HO-1 gene in a vari-
ety of  human cell types (endothelial cells, epithelial cells, 
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Figure 1  The heme oxygenase enzyme reaction. Heme is enzymatically 
degraded to yield carbon monoxide, iron and biliverdin (which is converted into 
bilirubin in a coupled reaction). CO: Carbon monoxide; NADP: Nicotinamide 
adenine dinucleotide phosphate; NADPH: β-Nicotinamide adenine dinucleotide 
2'-phosphate reduced tetrasodium salt.
T cells)[5]. The short guanosine/thymine (GT)n[12] repeat 
in the HO-1 gene promoter may provide protective ef-
fects against carotid atherosclerosis in individuals with a 
high level of  arsenic exposure. Therefore, the translation 
of  HO-1 research from “bench to bedside” must be car-
ried out carefully, with the appreciation that the response 
of  HO-1 gene expression to certain stimuli may be differ-
ent in humans and rodent models[9]. 
HEME OXYGENASE-1 PROMOTER 
POLYMORPHISMS
There are 3 possible polymorphisms in the 5’ flanking re-
gion: a (GT)n dinucleotide length polymorphism and two 
single nucleotide polymorphisms (SNP). Functional poly-
morphic dinucleotide guanosine/thymine (GT) repeat 
regions are present in the proximal promoter region of  
HO-1 approximately encompassing nucleotides -248 to 
-198, relative to the transcription start repeats regions in 
the HO promoter. The reported number of  GT-repeats 
range from 12 to 40, although a bimodal distribution ex-
ists in most populations, with the main alleles being com-
posed of  23 or 30 repeats. HO-1 mRNA expression and 
enzyme expression are greater when GT-repeat lengths 
are short and lesser when they are long[9]. There is some 
evidence that links H2O2 or other HO-1 transcriptional 
activators and the number of  GT repetitions and it has 
been postulated that conformational changes account for 
the modulation of  transcriptional activity. For instance, a 
left-handed double-helix structure (Z-DNA conforma-
tion) may be formed by the alternating purine-pyrimidine 
sequences, an arrangement that has been correlated with 
diminished transcriptional activity in other genes[3]. In-
deed, Yamada et al[13] observed that GT-dinucleotide re-
peat polymorphisms in the promoter region of  the HO-1 
gene were frequently associated with increased HO-1 
responses to exogenous stimuli.
The inducibility of  HO-1 is affected by (GT)n poly-
morphisms[14], as well as the SNP A(-413)T, in the pro-
moter of  HO-1[8]. Both short (GT)n alleles and the A-al-
lele have been associated with increased HO-1 promoter 
activity[4]. For instance, in 308 liver transplantations, 
HO-1 patient genotypes were correlated with outcome 
variables[15]. With respect to their (GT)n genotype, liver 
samples were divided into two classes - those containing 
short alleles (less than 25 repeats; class S) and those con-
taining long alleles (greater than or equal to 25 repeats; 
class L). Haplotype analyses confirmed the dominance of  
the A (-413)T SNP over (GT)n polymorphism[16].
The results of  transient transfection assays using lu-
ciferase promoter constructs were consistent with in vitro 
assays carried out in lymphoblastoid cell lines containing 
HO-1 GT repeats of  various lengths[9]. Cells homozygous 
for short GT-stretches had significantly greater HO-1 
expression and resistance to oxidant-induced apoptosis 
compared with cells homozygous for long GT-stretches, 
demonstrating that polymorphisms in GT-stretch length 
are functionally significant[9].
Hyperbilirubinemia is associated with multiple repeats 
of  TA nucleotides, as well as with the 211 G mutation, 
which are polymorphisms found in the UGT1A1 gene 
promoter[15] and coding regions, respectively[1]. However, 
it is not clear how these polymorphisms influence over-
all bilirubin levels and whether polymorphisms in other 
genes involved in the bilirubin metabolism pathway also 
influence overall bilirubin levels[3]. Although the short 
repeats found in certain HO alleles (< 25 repeats) have 
been found to have beneficial effects on the serum biliru-
bin levels and lipid profiles of  patients with coronary ar-
tery disease (CAD), few studies have examined the effects 
of  these repeats in healthy patients with normal bilirubin 
levels or patients who carry short GT-repeats (within in 
the HO-1 promoter) who are at a high risk for develop-
ing unconjugated hyperbilirubinemia[17]. Considering the 
antioxidant and anti-atherogenic properties of  bilirubin, 
the beneficial effects of  the S allele on serum bilirubin 
levels in carriers might be sufficient to exert a protective 
effect against the development and clinical severity of  
CAD[3].
Taha et al[18] have shown that pentoxifylline (PTX, a 
drug used to improve blood flow in patients with circula-
tion problems) in fibrosarcoma L292 cells strongly induc-
es the expression of  HO-1. The potential involvement of  
HO-1 in the regulation of  PTX signaling is of  particular 
importance, especially with respect to human HO-1 pro-
moter polymorphisms[19]. The presence of  alleles with 
lower activity (resulting in lower HO-1 expression) was 
demonstrated to be a contributing factor to increased risk 
of  cardiovascular complications, at least in some popula-
tions of  patients[5]. The cytoprotective effects of  PTX 
treatment were reproduced by incubation with hemin 
(an HO-1 activator)[5] or with CORM (a compound that 
causes the release of  CO)[15]. These effects were blocked 
by treatment with ZnPPIX (zinc protoporphyrin-IX)[20], 
an HO-1 inhibitor[15]. Thus, both PTX and HO-1 appear 
to have anti-inflammatory properties, as exemplified by 
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Figure 2  A variety of stimuli induce heme oxygenase-1 expression, a wide 
array of hepatotoxic chemicals and conditions conferring an adaptive 
cytoprotective response. HO-1: Heme oxygenase-1; UV: Ultraviolet.
ducible nitric oxide synthase[5] and regulation of  protein 
kinases C (which have effects on vascular smooth muscle 
cells)[6]. Exogenous CO can be delivered in both an in vivo 
model and in vitro model, as either a gaseous molecule 
or in the form of  innovative CO-releasing molecules 
(CORM) that are currently being developed by Hemo-
CORM and Alfama Inc[3,19].
HO-1 expression protective effects are linked to a 
combination of  factors, such as  removal of  the reac-
tive substrate heme, the biological effects of  the reaction 
products, the suppressive effects on monocyte chemo-
attractant protein 1, and modulation of  cell-cycle regula-
tors[7]. It has been suggested that activated Kupffer cells 
play an important role in the pathogenesis of  fulminant 
hepatic failure, as reflected by the activation of  both pro 
and anti-inflammatory cascades in the innate immune sys-
tem[8]. Recent studies have identified serum HO-1 levels 
as a novel diagnostic marker for macrophage activation 
under conditions including sepsis and hemophagocytic 
syndrome, which is useful for predicting the severity and 
prognosis of  acute liver injury[1,5].
Kawakami et al[22] have confirmed that T helper type 
17 (Th17) cells IL-17-producing CD4+ T cells[25] have a 
fundamental role in the immunopathogenesis of  experi-
mental autoimmune encephalomyelitis (EAE). Hamm-
erich et al[26] demonstrated that myeloid HO-1 deficiency 
exacerbated EAE in mice and enhanced infiltration of  
activated macrophages and Th17 cells to the central ner-
vous system, thereby establishing HO-1 as a critical early 
mediator of  the innate immune response in EAE[3]. 
The liver is a primary source of  the IL-7 response 
to Toll-like receptor (TLR) stimulation, although IL-7 
expression in the liver is limited under steady state con-
ditions[27]. TLR-mediated systemic cytokine expression 
alters protein expression[9,15]. Profiles in hepatocytes, 
which produce a number of  acute phase response pro-
teins, show markers of  systemic inflammation, including 
ferritin[28], plasminogen and complement components[9] 
in ischemia-reperfusion injury (IRI)[5]. IL-7 is an impor-
tant survival factor for T cells and is expressed in the 
liver as an acute phase reactant in response to inflam-
mation, which allows the immune system to respond to 
pathogens[9]. IL-7 expression is increased in the liver and 
kidney tissues only following TLR stimulation, whereas 
it decreased in the spleen and lymph nodes[27,29]. These 
results suggest that systemic hepatocyte-mediated IL-7 
expression (but not expression mediated by the lymphoid 
organs) plays an important role in IL-7 mediated T cell 
homeostasis in response to infection[9].
In recent years, the immunomodulatory capacity of  
the adaptive responses by HO-1 has received more atten-
tion. It has been reported that HO-1 can promote graft 
tolerance by activation/production of  CD4+/CD25+ 
regulatory T cells (Tregs) or by promoting the activation-
induced cell death of  T cells[8]. CD4+/CD25+/Foxp3+ 
Tregs are a functionally distinct subset of  mature T cells 
with broad suppressive activity[9]. Tregs play a key role in 
the maintenance of  peripheral tolerance and Treg defi-
the inhibition of  interleukin (IL)-1β, IL-6, IL-8, TNF-a 
and granulocyte-macrophage colony-stimulating factor 
expression, and the induction of  IL-10 expression[15,21]. 
Furthermore, the expression of  both genes has been 
shown to reduce proliferation, migration and adhesion 
of  leukocytes to endothelial cells, through inhibition of  
CD25 and ICAM-1[6].
Thus, one can expect that the efficacy of  PTX treat-
ment is likely to be influenced by these polymorphisms 
and the efficacy of  this treatment is likely to be low in 
patients with less active HO-1 alleles[15].
The HO-1 genotype is associated with liver transplan-
tation outcome and these findings suggest that HO-1 
mediates graft survival following liver transplantation[1,5]. 
Therefore, the expression of  the HO-1 gene may be al-
tered by the number of  (GT)n repeats and could play an 
important role in modulating vascular tone under differ-
ent pathological situations[3].
MODULATORY AND CYTOPROTECTIVE 
EFFECTS OF HO-1 
Induction of  HO-1 and its metabolites has a protective 
effect in a large number of  seemingly unrelated pa-
thologies, including sepsis, malaria[20], endotoxic shock, 
ischemic reperfusion injury (IRI)[4], organ transplant 
rejection[22], induction of  tolerance myocardial infarc-
tion, type 2 diabetes[15] and obesity[23]. This wide spec-
trum of  protective effects has been attributed to multi-
level mechanisms of  cytoprotection and inflammatory 
modulation. Three catabolic products, BV, BR and 
CO[22], and ferritin (which is induced by free iron[2]) have 
been implicated in HO-1 control of  apoptosis and cell 
proliferation. However, the effects of  BV/BR and CO 
do not overlap in terms of  their effects on cell signaling 
and target molecules. The beneficial effects of  the three 
products generated by HO-1 differ not only in their 
inherent molecular mechanisms, but also in their down-
stream cellular targets. To date, this is the only enzymatic 
system known to exhibit such characteristics; a good ex-
ample of  this is the manner in which HO-1 regulates the 
cell cycle - it increases endothelial cell (EC) proliferation 
but simultaneously decreases airway and vascular smooth 
muscle cell cycle progression[4]. A number of  intracel-
lular signaling molecules have been identified as being 
involved in regulating the induction of  HO-1; among 
which upstream signaling kinases, extracellular signal-
regulated protein kinase (ERK), c-Jun N terminal kinase 
and p38 mitogen activated protein kinase (MAPK) have 
been considered to play major roles in controlling up-
regulation of  HO-1[24]. Activation of  either one or more 
of  these MAPKs by external stimuli triggers HO-1 gene 
expression. ERK1/2 and p38 MAPK are involved in the 
induction of  HO-1 gene transcription by sodium arsenite 
in the hepatoma cell line.
CO acts through a variety of  pathways, including 
increased cycling of  guanosine monophosphate through 
the activation of  guanylate cyclase[15], modulation of  in-
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ciencies can lead to progressive autoimmune disorders[5]. 
Similarly, increased Treg function can prevent allograft re-
jection and suppress tumor immunity[15] during allogeneic 
hematopoietic stem cell transplantation (HSCT)[9]. Tregs 
have been shown to play an important role in establish-
ing tolerance between recipient tissues and donor-derived 
immunity. This was initially demonstrated in murine stud-
ies in which the depletion of  Tregs from stem cell grafts 
resulted in increased graft-versus-host disease (GVHD) 
and increased Treg levels resulted in the suppression of  
GVHD following transplant[5]. Patients with active chron-
ic GVHD have lower Treg levels when compared with 
patients without chronic GVHD[15].
Recent studies have suggested that IL-7 and IL-15 are 
the primary homeostatic cytokines that drive CD4+ T cell 
proliferation[25]. Previous analyses found that plasma IL-7 
levels are consistently higher following allogenic HSCT, 
but IL-7 levels do not correlate with the degree of  CD4+ 
T-cell recovery. Thus, IL-7 may promote T-cell expan-
sion following transplants, but high plasma levels of  IL-7 
persist after lymphopenia has resolved[15]. Unbalanced 
Th1/Th2 T-cell responses in the liver are a characteristic 
of  hepatic inflammation and subsequent liver fibrosis. 
The recently discovered Th17 cells, a subtype of  CD4(+) 
T-helper cells mainly producing IL-17 and IL-22, have 
initially been linked to host defense against infections and 
to autoimmunity.
HO-1 is not essential for TLR4/MyD88-induced NF-
kB/MAPK activation and the subsequent pro-inflamma-
tory cytokine production, but it is required for TLR4/
TLR3/IRF3-induced production of  IFN-γ[30], as well as 
the expression of  primary IRF3-target genes in macro-
phages. IRF3 activation and subsequent IFN-γ produc-
tion is severely impaired in HO-1 knockout macrophages 
infected with Sendai virus (SeV) used to down regulate 
HO-1 expression[31]. In the presence of  polyI:C, myeloid 
HO-1 knockout mice infected with Listeria monocytogenes 
(an infection model showing enhanced severity that is 
dependent on IFN-γ production) showed increased levels 
of  bacterial clearance, whereas control mice succumbed 
to infection[1,30].
Lee and Bai et al[12] identified a potential interplay 
between IL-10 and HO-1 in the inhibition of  LPS-
induced inflammatory responses in macrophages. They 
also provided evidence that HO-1 mediates the anti-
inflammatory function of  IL-10, both in vivo, and that 
IL-10 and HO-1 activate a positive feedback circuit to 
amplify the anti-inflammatory response[15]. IL-10 and 
HO-1 were up-regulated in patients receiving norfloxa-
cin and correlated with norfloxacin in a concentration-
dependent manner, whereas proinflammatory inducible 
nitric oxide synthase, cyclooxygenase-2 and NF-kB 
behaved inversely. Higher IL-10 levels correlated with 
lower white blood cell count and higher mean arterial 
pressure. No correlations were found between IL-10 
and disease clinical scores or liver function markers in 
blood[9].
THE PHYSIOLOGICAL ROLE OF THE HO-1 
GENE IN THE LIVER 
The liver is the largest gland in the body and is situated 
slightly below the diaphragm and anterior to the stom-
ach. It consists of  two lobes that are wedge-shaped. Two 
blood vessels enter the liver, namely the hepatic portal 
vein, with dissolved food substances from the small in-
testine, and the hepatic artery, with oxygenated blood 
from the lungs[8,32]. Two ducts originate in the liver and 
these unite to form the common hepatic duct which 
opens with the pancreatic duct in the hollow side of  the 
duodenum (the first section of  the small intestine). The 
gall bladder lies inside the liver and is the storage place 
for bile, which is formed by the liver cells[8].
The hepatic microvasculature is a unique and well-
organized system of  microvessels, which are composed 
of  parenchymal hepatocytes and a variety of  non-paren-
chymal cells, such as sinusoidal endothelial cells, Kupffer 
cells[33] and Ito cells. Cytochrome P450[34] is a major con-
tributor to production of  bilirubin derived from non-
hemoglobin sources in the liver[1].
HO-1 is expressed at low to undetectable levels in he-
patocytes and is expressed mainly in Kupffer cells under 
basal conditions[33]. However, HO-1 undergoes a rapid 
transcriptional activation in both Kupffer cells and hepa-
tocytes in response to noxious stimuli[35]. A physiological 
role for HO-1 gene expression has also been demon-
strated in HO-1 deficient mice and in one case of  human 
genetic HO-1 deficiency. Both murine and human HO-1 
deficiencies have systemic manifestations associated with 
iron metabolism, such as hepatic overload (with signs 
of  a chronic hepatitis) and iron-deficiency anemia (with 
paradoxical increased levels of  ferritin)[7]. Determining 
the role that HO-1 plays in such regulatory mechanisms 
has become increasingly relevant in recent years because 
its induction has been shown to prevent ethanol-induced 
inflammation in the intestine[36] and liver[4], as well as in 
the prevention of  oxidative damage to hepatocytes[5].
MECHANISMS OF ACTION OF HMOX-1 
IN THE LIVER
Hepatic ischemia and IR are the leading causes of  clini-
cal liver damage and occur[5] during major trauma con-
comitant with blood loss, extensive liver resection during 
tumor removal and liver transplantation[37]. Steatosis is a 
major risk factor for liver surgery because steatotic liv-
ers respond poorly to IRI. The predominant form of  
hepatocyte death is caused by apoptosis in ischemic non-
steatotic livers, whereas steatotic livers develop massive 
necrosis following ischemic injury[1]. Mitochondria are the 
main cellular source of  reactive oxygen species (ROS), 
which are observed to be dramatically increased in stea-
totic livers during the reperfusion period[38]. Increased 
ROS generation results in increased hepatic lipid peroxi-
dation and oxidative stress, as well as decreased adenosine 
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triphosphate generation, which may partially explain the 
poor tolerance of  steatotic livers to IRI. Increased neu-
trophil accumulation causes significant sinusoidal endo-
thelial cell injury through the release of  free radicals and 
proteases, which may further aggravate hepatic microcir-
culation via the dysregulation of  vasoactive mediators[1]. 
Kupffer cells activation is also reported to be involved in 
the poor outcomes of  patients with steatotic livers[4]. Oxi-
dative injury leads to hepatocyte damage followed by acti-
vation of  Kupffer cells and results in the production of  a 
number of  inflammatory cytokines, including TNF-a and 
IL-6. These results suggest that the HO system has a po-
tent protective effect on acute liver injury induced by car-
bon tetrachloride, CCl4. In rats, CXCL14 expression was 
increased in the liver injury phase and returned to normal 
after[2] liver regeneration, suggesting its involvement in 
the liver injury or regeneration regulation[5,9]. Inhibition 
of  HO-1 has been shown to protect against tissue injury 
in livers exposed to CCl4[11,39]. Animals pretreated with 
hemin and then exposed to CCl4 showed a reduced leu-
kocyte infiltration. Elevated HO activity has also been 
observed in damaged liver tissue, most likely due to inter-
ference with the HO pathway by tetrachloride-dependent 
metabolism triggered by heme overload-associated tox-
icity. Hepatocyte apoptosis and liver injury were both 
attenuated in rats pretreated with hemin[15]. Basal HO-1 
levels appear to be more critical than the ability to up-
regulate HO-1 in response to IRI and they may also be 
able to predict the success of  pharmacologically induced 
cytoprotection. Consistent with this, cobalt protoporphy-
rin (CoPP)[40]-induced HO-1 up-regulation suppresses the 
type-1 interferon pathway downstream of  the Toll-like 
receptor (TLR) 4 system in hepatic IRI models[8,17].
Orthotopic liver transplantation (OLT) is the best 
available treatment for patients with end-stage liver fail-
ure, during which the liver is exposed to some stressful 
stimuli, such as ischemia and reperfusion injury. HO-1 
has been shown to provide cytoprotection during liver 
ischemia and reperfusion[41]. 
HO-1 expression has been suggested to have an 
immune-modulatory effect[2] and up-regulation of  HO-1 
has been shown to protect livers from IRI and improve 
graft survival[1]. All of  the products formed during this 
process have potential beneficial effects in transplant set-
tings. CO has vasodilatory effects, which help to maintain 
microvascular hepatic blood flow[3], BV and BR, and 
possess potent antioxidant properties[1]. Free iron is itself  
highly reactive; however, the cellular Fe2+ released during 
heme degradation up-regulates the expression of  the Fe2+ 
sequestering protein ferritin, as well as an Fe2+ pump, 
thereby limiting the amount of  free iron and preventing 
the generation of  reactive oxygen species[8]. HO-1 partici-
pates in iron homeostasis. Javanmard et al[42] generated 
mice with targeted HO-1 null mutations and analyzed 
parameters of  iron metabolism and they discovered 
that adult HO-1-deficient animals develop both serum 
iron deficiency and pathological iron-loading, indicat-
ing that HO-1 is crucial for the expulsion of  iron from 
tissue stores.
HO-1 expression protects transplanted organs from 
IRI and immune rejection[8]. This review has demon-
strated that persistent over-expression of  HO-1 in donor 
livers can improve survival by expanding T regulatory 
cells in a model of  OLT[43]. The possible mechanisms 
by which CO protects the liver against cold ischemia-
reperfusion do not appear to be associated with down-
regulation of  the NF-kB-signaling pathway. ROS genera-
tion following re-oxygenation causes tissue damage and 
initiates a cellular cascade leading to inflammation, cell 
death and, ultimately, organ failure. A growing body of  
evidence suggests that Kupffer cells and T cells mediate 
the activation of  neutrophil inflammatory responses[33]. 
The activation of  TLRs in Kupffer cells may provide the 
triggering signal for pro-inflammatory responses in the 
IRI sequence[8]. Dissecting the signaling pathways that 
link HO-1 and TLR activation may be important in de-
vising novel therapeutic strategies for combating IRI[4]. 
The evolutionarily conserved sentinel TLR belong to 
the IL-1R family and recognize bacterial/viral-specific 
pathogen-associated molecular patterns[5]. TLRs trigger 
host inflammatory responses that are mediated by macro-
phages, neutrophils and complement[44]. The induced cy-
tokine mediators may then activate systemic responses to 
recruit leukocytes to sites of  inflammation. The cellular 
and molecular mechanisms by which hepatic microvascu-
lar flow is regulated during normal and disease conditions 
are being actively investigated[2].
Intraportal delivery of  an adeno-associated virus 
(AAV) expression vector encoding rat HO-1 (AAV-HO-1) 
resulted in persistent expression of  HO-1 in hepatocytes 
(and increased HO-1 activity)[45] in transplanted livers, 
leading to prolonged survival in recipients[15]. Over-
expression of  HO-1 reduced the Banff  rejection activity 
index, measured by ELISA, by inhibiting the  production 
of  IL-2 and TNF-a, decreasing infiltration of  CD4+ and 
CD8+ cells, and increased infiltration of  Treg cells into 
donor livers[5,46]. 
The spleens of  recipients expressed higher levels of  
Foxp3, TGF-β and IL-10 compared with control rats and 
the transplanted livers expressed higher levels of  Foxp3 
and TGF-β[47]. Splenocytes from tolerant recipients had 
higher levels of  Treg cells and responded poorly to allo-
geneic donor splenocytes. Persistent expression of  HO-1 
in donor livers by intraportal delivery of  AAV-HO-1 
improves survival by expanding the number of  Treg cells. 
The HO-1-based therapies described here are promising 
new strategies for the prevention of  liver transplant rejec-
tions[48]. 
During maturation, dendritic cells (DCs) inhabit a va-
riety of  microenvironments that contain different levels 
of  chemokines and chemokine receptors. Immature DCs 
express CCR1, CCR2, CCR5 and CXCR1, while mature 
DCs express high levels of  CCR7, CCL22, CCL5, CCL2 
and CXCL10[39]. In CoPPIX-treated mice, CCR7 was 
observed to be markedly down-regulated in liver DCs[49]. 
CoPPIX treatment reduced the expression of  CCL2 
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and CCL22, while the expression levels of  CXCL10 and 
CCL5 were unchanged[50]. These results indicate that 
HO-1 inhibits the phenotypic and functional maturation 
of  DCs, and thus reduces the ability of  DCs to stimulate 
CD4+ T cells[46], and the modulation of  Th2 cytokine 
production by donor-derived DC may contribute to the 
comparative immune privilege of  hepatic allografts[49,51].
HO-1 AS A POTENTIAL THERAPEUTIC 
TARGET IN LIVER DISEASES
Hepatitis C virus (HCV) represents a major public health 
burden in both industrialized and developing countries. 
HO-1 over-expression has been observed to decrease 
HCV replication, reduce pro-oxidant production in rep-
licon cells, and increase resistance to oxidative injury[52]. 
These findings strongly suggest potential therapeutic 
roles for HO-1[53]. Nevertheless, iron was recently shown 
to inhibit the activity of  HCV RNA-dependent RNA 
polymerase, as well as inhibiting replication in non-struc-
tural replicons[54]. However, a potential antiviral role for 
iron must be considered in the context of  clinical data 
showing that mild increases in iron storage correlate with 
progressive HCV liver disease and hepatic decompensa-
tion. Therefore, a potential role for biliverdin and carbon 
monoxide as inhibitors of  viral replication (via their anti-
oxidative effects) requires further study[53].
Recent advances in molecular biology have provided 
new approaches to reducing hepatic IRI with gene ther-
apy[55]. Liver transplantation[56] (a commonly employed 
treatment for hepatic failure) is still a limited means of  
therapy and has many drawbacks, including high mon-
etary costs for the patient and donor shortages[8]. Pres-
ently, there are a limited number of  strategies for protect-
ing liver cells from damage and degeneration[57]. Keeping 
in mind the increasing amount of  experimental evidence 
demonstrating the antioxidant and anti-inflammatory ef-
fects of  HO-1 products, induction of  this enzyme (or 
its catalytic activity) by either natural or synthetic com-
pounds may represent an effective strategy to intervene 
in liver carcinogenesis and other hepatic disorders[11]. 
A wide variety of  chemopreventive agents that elicit 
cytoprotective, anti-inflammatory and/or antioxidant 
effects by the induction of  HO-1 expression have been 
recognized[58]. While continuing efforts should be geared 
towards the search for novel hepatoprotective[59] agents 
targeting HO-1, certain synthetic or naturally occurring 
substances already identified appear to induce HO-1 ex-
pression as part of  their chemoprevention/chemoprotec-
tive effects against hepatocarcinogenesis[37] and should be 
further investigated.
Constitutive HO-1 expression by the Kupffer cells 
of  the liver has been shown to be beneficial in hepatic 
IRI treatment. The consequences of  HO-1 production 
have been shown to have antioxidant, anti-inflammatory, 
anti-proliferative, anti-apoptotic, immunomodulatory and 
vasorelaxant effects[60].
CONCLUSION
The HO-1 system may play an important role in various 
pathophysiological conditions. Thus, pharmacological 
modulation of  the HO-1 system may represent an ef-
fective and cooperative strategy to mitigate liver injury 
in HCV, although the exact effects are likely to differ 
depending on the type of  disease. Therefore, down-reg-
ulating the HO-1 system by pharmacological or genetic 
means may represent a new therapeutic approach for 
the management of  liver injury. A comprehensive un-
derstanding of  the mechanisms underlying the observed 
effects of  HO-1 and its products will be needed before 
their use can be evaluated in clinical applications for the pre-
vention and/or treatment of  human diseases, such as HCV.
There are wide-ranging biological implications for 
HO-1 expression, extending far beyond its initial identi-
fied role as the rate-limiting enzyme in heme degradation. 
The tight regulation of  HO-1 gene transcription and the 
lack of  high levels of  constitutive expression reflect the 
great potential of  this “protective” gene for inducing in-
jury under certain conditions. Each HO-1 reaction prod-
uct can be harmful and (in sufficient quantities) cause 
tissue injury, with resulting enhanced susceptibility to oxi-
dative stress. Thus, HO-1 is not exclusively cytoprotective 
or cytotoxic, but it is involved in a complex equilibrium 
of  inflammatory and reparative cellular processes.
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